Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with ...
Sobi (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant (emapalumab) for interferon-gamma (IFN?)-driven ...
Professors Yao Yongming and Du Xiaohui, leading a research group at the Chinese PLA General Hospital, have published groundbreaking findings demonstrating that CD4+ T lymphocytes undergo PANoptosis ...
Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer baseAdvance SeaStar Medical’s ...
New research reveals that aging immune cells can become locked in a self-sustaining inflammatory state, worsening the body’s ...
XORTX Therapeutics Inc. ("XORTX" or the "Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical ...
Xortx Therapeutics announces pioneering research on genome-wide pathogenic pathways in gout: Calgary, Alberta Saturday, January 3, 2026, 13:00 Hrs [IST] Xortx Therapeutics Inc., a ...
Researchers have identified serine threonine kinase 10 as a key regulator of platelet function, haemostasis and ...
The Food and Drug Administration has approved Yartemlea ® (narsoplimab-wuug) for the treatment of adult and pediatric patients aged 2 years and older with hematopoietic stem cell transplant ...
Omeros’ Yartemlea gets US FDA approval to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy: Seattle Monday, December 29, 2025, 12:00 Hrs [IST] Omer ...
SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments ...
Acute sepsis profoundly changes how intravenous fluids behave within the body. Using a sheep model, researchers investigated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback